Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Q1 2021 Syndax Pharmaceuticals Inc Earnings Call Transcript

May 11, 2021 / 08:30PM GMT
Release Date Price: $16.04 (+2.56%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Syndax First Quarter 2021 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Melissa Forst of Argo Partners. Please go ahead.

Melissa Forst
Argot Partners, LLC - SVP

Thank you. Welcome, and thank you to those of you joining us on the line and the webcast this afternoon for a review of Syndax's first quarter 2021 financial and operating results.

With me this afternoon to discuss the results and provide an update on the company's progress are Dr. Briggs Morrison, Chief Executive Officer; Daphne Karydas, Chief Financial Officer. Also joining us on the call today for the question-and-answer session will be Michael Metzger, President and Chief Operating Officer; Dr. Michael Meyers, Chief Medical Officer; and Dr. Peter Ordentlich, Chief Scientific Officer.

This call is being accompanied by a slide deck that has been

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot